Relieves bronchospasm. ANDA 208884, held by Zydus Pharmaceuticals (USA). Albuterol Sulfate.
As of Nov 18, 2026, ANDA 208884 (Albuterol Sulfate), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Oct 22, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol tablets, USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2020 | Original application | Approved | None posted |
| Albuterol SulfateEQ 2MG BASE · tablet;oral | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 4MG BASE · tablet;oral | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters